Mary Szela has served as a member of our board of directors since July 2025. Ms. Szela has served as CEO and President of TriSalus Life Sciences since January 2018. Prior to joining TriSalus, Ms. Szela served as CEO of Aegerion Pharmaceuticals, Inc., from 2016 through Aegerion s merger with QLT Inc. to form Novelion Therapeutics Inc., where, until 2017, she served as CEO. Prior to Novelion, she was CEO of Melinta Therapeutics, leading the company s revitalization effort and accelerating clinical development of its lead asset for treatment of MRSA (methicillin-resistant Staphylococcus aureus). Previously, Ms. Szela held progressive leadership roles at Abbott Laboratories including President of the company s $8 billion U.S. pharmaceutical business. She developed global brands such as Humira and served as Senior Vice President for global strategic marketing and services. Ms. Szela currently serves as a member of the Board of Directors for Kura Oncology, Prometheus Biosciences, Omega Therapeutics and Senda Biosciences. She received both her B.S. in Nursing and her MBA from the University of Illinois at Chicago. We believe Ms. Szela is qualified to serve on our board of directors based on her substantial business, leadership and management experience in the biotechnology sector.